Physician profile
John Gil
NPI 1376541912
$11,169.80
in general payments reported to CMS, 2019-2025
43 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,007 · 2020: $1,953 · 2021: $1,729 · 2022: $1,704 · 2023: $1,184 · 2024: $1,074 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520 · Honoraria: $250 · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,520.23 |
| Honoraria | $250.00 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,148.39 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,119.37 | 2019-2025 | Jardiance, Zepbound, Emgality |
| Amgen INC. | $1,006.99 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $820.30 | 2019-2025 | |
| Abbvie INC. | $741.11 | 2019-2025 | |
| Novo Nordisk INC | $727.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $705.36 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Amarin Pharma, INC. | $689.12 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $502.61 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $406.88 | 2019-2025 | |
| Inspire Medical Systems, INC. | $344.50 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $340.02 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $275.35 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Idorsia Pharmaceuticals US INC | $251.06 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $244.86 | 2023-2025 | Cologuard Collection Kit |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.